104 related articles for article (PubMed ID: 25658377)
1. Glycoproteomic comparison of clinical triple-negative and luminal breast tumors.
Hill JJ; Tremblay TL; Fauteux F; Li J; Wang E; Aguilar-Mahecha A; Basik M; O'Connor-McCourt M
J Proteome Res; 2015 Mar; 14(3):1376-88. PubMed ID: 25658377
[TBL] [Abstract][Full Text] [Related]
2. Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers.
Rao D; Kimler BF; Nothnick WB; Davis MK; Fan F; Tawfik O
Hum Pathol; 2015 Jun; 46(6):876-83. PubMed ID: 25841305
[TBL] [Abstract][Full Text] [Related]
3. Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer.
Yamashita Y; Nishiumi S; Kono S; Takao S; Azuma T; Yoshida M
BMC Cancer; 2017 Aug; 17(1):589. PubMed ID: 28851309
[TBL] [Abstract][Full Text] [Related]
4. MR imaging features of triple-negative breast cancers.
Sung JS; Jochelson MS; Brennan S; Joo S; Wen YH; Moskowitz C; Zheng J; Dershaw DD; Morris EA
Breast J; 2013; 19(6):643-9. PubMed ID: 24015869
[TBL] [Abstract][Full Text] [Related]
5. [Survival of patients with metastatic breast cancer according to pathological types of tumors].
Sánchez R C; Acevedo C F; Petric G M; Galindo A H; Domínguez C F; León R A; Razmilic V D; Ceballos C; Espinoza F; Navarro O ME; Oddó B D; Camus A M
Rev Med Chil; 2014 Apr; 142(4):428-35. PubMed ID: 25117032
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.
Lefort S; Joffre C; Kieffer Y; Givel AM; Bourachot B; Zago G; Bieche I; Dubois T; Meseure D; Vincent-Salomon A; Camonis J; Mechta-Grigoriou F
Autophagy; 2014; 10(12):2122-42. PubMed ID: 25427136
[TBL] [Abstract][Full Text] [Related]
7. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
[TBL] [Abstract][Full Text] [Related]
8. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
9. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
10. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
[TBL] [Abstract][Full Text] [Related]
11. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
12. Label-free proteomic analysis of breast cancer molecular subtypes.
Panis C; Pizzatti L; Herrera AC; Corrêa S; Binato R; Abdelhay E
J Proteome Res; 2014 Nov; 13(11):4752-72. PubMed ID: 25221861
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
Bhargava R; Beriwal S; Dabbs DJ; Ozbek U; Soran A; Johnson RR; Brufsky AM; Lembersky BC; Ahrendt GM
Cancer; 2010 Mar; 116(6):1431-9. PubMed ID: 20131351
[TBL] [Abstract][Full Text] [Related]
14. [Breast cancer with triple-negative phenotype in the Russian patient population. Clinical and morphologic features].
Zhukova LG
Vopr Onkol; 2015; 61(2):189-94. PubMed ID: 26087596
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
16. The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype.
Panis C; Pizzatti L; Corrêa S; Binato R; Lemos GF; da Silva do Amaral Herrera AC; Seixas TF; Cecchini R; Abdelhay E
Cancer Lett; 2015 Feb; 357(1):186-195. PubMed ID: 25434795
[TBL] [Abstract][Full Text] [Related]
17. Shotgun proteomics of archival triple-negative breast cancer samples.
Gámez-Pozo A; Ferrer NI; Ciruelos E; López-Vacas R; Martínez FG; Espinosa E; Vara JÁ
Proteomics Clin Appl; 2013 Apr; 7(3-4):283-91. PubMed ID: 23436753
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of HER2-positive and triple-negative status in small (≤ 1 cm) node-negative breast cancer.
Gorshein E; Klein P; Boolbol SK; Shao T
Clin Breast Cancer; 2014 Oct; 14(5):309-14. PubMed ID: 24703318
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging features in triple-negative breast cancer: comparison with luminal and HER2-overexpressing tumors.
Costantini M; Belli P; Distefano D; Bufi E; Matteo MD; Rinaldi P; Giuliani M; Petrone G; Magno S; Bonomo L
Clin Breast Cancer; 2012 Oct; 12(5):331-9. PubMed ID: 23040001
[TBL] [Abstract][Full Text] [Related]
20. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
